---
title: "VK2735 in Chronic weight management: Expected outcomes of therapy"
description: "Formulary evidence on VK2735 in Chronic weight management: Expected outcomes of therapy. Topics: Cardiovascular events: semaglutide 2.4 mg in SELECT, Weight loss sustained to 4 years in SELECT, Progression to type 2 diabetes: tirzepatide over 176 weeks in SURMOUNT-1, Obstructive sleep apnea: tirzepatide in SURMOUNT-OSA, and 4 further topics. 8 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/expected-outcomes-of-therapy"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Expected outcomes of therapy

<a id="heading-2.2.2.7"></a>

## 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

### Cardiovascular events: semaglutide 2.4 mg in SELECT

> “A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001).”
> “Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001).”

Source: [Lincoff et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37952131/)

<a id="topic-2.2.2.7-2"></a>

### Weight loss sustained to 4 years in SELECT

> “In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years. At 208 weeks, semaglutide was associated with mean reduction in weight (−10.2%), waist circumference (−7.7 cm) and waist-to-height ratio (−6.9%) versus placebo (−1.5%, −1.3 cm and −1.0%, respectively; P < 0.0001 for all comparisons versus placebo).”

Source: [Ryan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11271387/)

<a id="topic-2.2.2.7-3"></a>

### Progression to type 2 diabetes: tirzepatide over 176 weeks in SURMOUNT-1

> “At 176 weeks, the mean percent change in body weight among the participants who received tirzepatide was -12.3% with the 5-mg dose, -18.7% with the 10-mg dose, and -19.7% with the 15-mg dose, as compared with -1.3% among those who received placebo (P<0.001 for all comparisons with placebo).”
> “Fewer participants received a diagnosis of type 2 diabetes in the tirzepatide groups than in the placebo group (1.3% vs. 13.3%; hazard ratio, 0.07; 95% confidence interval [CI], 0.0 to 0.1; P<0.001).”

Source: [Jastreboff et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39536238/)

<a id="topic-2.2.2.7-4"></a>

### Obstructive sleep apnea: tirzepatide in SURMOUNT-OSA

> “In trial 1, the mean change in AHI at week 52 was −25.3 events per hour (95% confidence interval [CI], −29.3 to −21.2) with tirzepatide and −5.3 events per hour (95% CI, −9.4 to −1.1) with placebo, for an estimated treatment difference of −20.0 events per hour (95% CI, −25.8 to −14.2) (P<0.001).”
> “In trial 2, the mean change in AHI at week 52 was −29.3 events per hour (95% CI, −33.2 to −25.4) with tirzepatide and −5.5 events per hour (95% CI, −9.9 to −1.2) with placebo, for an estimated treatment difference of −23.8 events per hour (95% CI, −29.6 to −17.9) (P<0.001).”

Source: [Malhotra et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11598664/)

<a id="topic-2.2.2.7-5"></a>

### Heart failure with preserved ejection fraction: semaglutide 2.4 mg in STEP-HFpEF

> “The mean change in the KCCQ-CSS was 16.6 points with semaglutide and 8.7 points with placebo (estimated difference, 7.8 points; 95% confidence interval [CI], 4.8 to 10.9; P<0.001), and the mean percentage change in body weight was -13.3% with semaglutide and -2.6% with placebo (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001).”
> “The mean change in the 6-minute walk distance was 21.5 m with semaglutide and 1.2 m with placebo (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001).”

Source: [Kosiborod et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37622681/)

<a id="topic-2.2.2.7-6"></a>

### Steatohepatitis: semaglutide 2.4 mg in ESSENCE

> “Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group (estimated difference, 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001).”
> “A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group (estimated difference, 14.4 percentage points; 95% CI, 7.5 to 21.3; P<0.001).”

Source: [Sanyal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40305708/)

<a id="topic-2.2.2.7-7"></a>

### Glycemic outcomes associated with 5% to 10% weight loss

> “Weight loss of 5% to 10% is associated with hemoglobin A1c reductions of 0.6% to 1.0% and reduced need for diabetes medications.”

Source: [Jensen et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5819889/)

<a id="topic-2.2.2.7-8"></a>

### Health care spending associated with weight loss

> “In this cross-sectional study of 17 209 adults, among those with employer-sponsored insurance, adults with a baseline BMI of 30 were estimated to spend 7% less following the loss of 5% of BMI and 30% less following the loss of 25% of BMI. Similar results were found for Medicare adults.”

Source: [Thorpe and Joski (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11621981/)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
